Scottish Enterprise

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative solutions for extracorporeal treatments. The company's flagship product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures such as dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes in long-term dialysis treatments.

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

Ilosta specializes in developing novel technology to reduce the cost, time, and dangers associated with monitoring the health of engineering structures and extending their lifespan without requiring human intervention.

Microplate Dx is a developer of innovative diagnostic technology aimed at addressing the critical global health issue of antimicrobial resistance, which leads to drug-resistant infections. Originating as a spinout from the University of Strathclyde in Glasgow, the company focuses on creating solutions that significantly reduce fatalities associated with these infections. Its core technology utilizes highly sensitive biosensor electrodes paired with miniaturized hydrogel deposits containing antibiotics specifically designed for the infections being tested. This approach offers a low-cost, accurate point-of-care diagnostic device that enables timely and optimal antibiotic prescribing, allowing healthcare providers to deliver effective treatments in under one hour. Microplate Dx's mission is to enhance antibiotic stewardship and proactively combat the rise of antimicrobial resistance worldwide.

Manus Neurodynamica Ltd is a company based in North Shields, United Kingdom, established in 2008. It specializes in the development of medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson’s disease. The company’s innovative device serves as a triage tool that facilitates early diagnosis by analyzing minute limb and hand movements to quantify fine motor skills. This technology, coupled with advanced analytical software, enables clinicians to effectively assess patient movement parameters, thereby enhancing the accuracy of diagnoses and improving the efficiency of neuromotor services. Manus Neurodynamica's solutions are utilized in various settings, including academic research and pharmaceutical studies, as well as in non-medical applications.

IbisVision Limited is a company that specializes in developing visual field test software aimed at the early detection of glaucoma, a leading cause of blindness. Its flagship product, Ring of Sight, utilizes patented technology to offer a unique eye testing experience through a cloud-based application that can be accessed remotely from various locations. The software consolidates multiple eye tests into one device, allowing healthcare professionals to conduct both in-practice and no-contact testing. This innovative approach not only enhances patient care but also supports optometrists in maximizing operational efficiency. Founded in 2013 and located in Livingston, United Kingdom, IbisVision is committed to improving eye care by providing a reliable and secure platform for diagnosing and monitoring glaucoma. The application ensures data privacy through secure encrypted servers, underscoring the company's dedication to maintaining high standards of patient confidentiality and security.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

PneumoWave is a company focused on developing advanced real-time monitoring solutions for patients with respiratory conditions. Utilizing proprietary sensor technology and an AI-driven digital therapeutic software platform, PneumoWave enables patients and healthcare providers to track respiratory rates and performance outside of clinical settings, such as at home or work. The company's innovative biosensors continuously capture and wirelessly transmit data for analysis, allowing for the accurate detection of various respiratory adverse events. This system includes an alert mechanism that promptly notifies healthcare professionals, facilitating timely interventions and improving patient outcomes. By enabling doctors to better manage medication use, identify early signs of deterioration, and reduce hospital admissions and in-person appointments, PneumoWave aims to transform respiratory care through proactive monitoring and intervention.

Hearing Diagnostics Limited is a health-tech company based in Edinburgh, United Kingdom, founded in 2017. The company specializes in developing and manufacturing innovative hearing screening and diagnostics products aimed at addressing unmanaged hearing loss. One of its key offerings is the Audimetroid, a device that employs head motion sensors for localized hearing screening. This technology enables effective and cost-efficient hearing assessments, allowing nurses, audiologists, otolaryngologists, and trained technicians to conduct objective screenings in various community environments. By utilizing spatially-localized sounds and inertia measurement sensors, Hearing Diagnostics Limited aims to facilitate earlier management of hearing loss, ultimately improving the quality of life for individuals affected by this condition.

BioCaptiva is a company focused on advancing liquid biopsy technology for the early diagnosis and monitoring of challenging-to-detect cancers. The company's innovative platform captures circulating free DNA from patients' blood in greater quantities than existing methods, addressing the limitations of current liquid biopsy tests. By enhancing the ability to detect and monitor cancer, BioCaptiva aims to provide healthcare professionals with improved tools for disease management, ultimately transforming the landscape of cancer diagnostics.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Aiber is a company that develops innovative software and medical support systems aimed at enhancing emergency care in international first response scenarios. By utilizing Bluetooth sensors, Aiber's solutions enable wireless monitoring of vital signs, facilitating the detection of patient deterioration or improvement. Their medical-grade sensors empower crews to effectively manage medical emergencies in various environments, including air and sea travel. This technology allows for the seamless sharing of vital sign data with ground-based medical providers, ensuring consistent and informed care for passengers during flights. Overall, Aiber is dedicated to improving medical response capabilities and supporting remote healthcare initiatives.

WellFish Diagnostics is a company dedicated to enhancing the sustainability of the aquaculture industry by improving fish health and welfare. Founded in 2021 by Brian Quinn, the company is headquartered in Bridge of Weir, United Kingdom. WellFish Diagnostics focuses on providing health monitoring services for fish, including smoltification, toxicity assessment, and aquafeed optimization. Their goal is to develop a dynamic diagnostic platform that adapts to the evolving needs of the rapidly growing aquaculture sector, helping industrialists reduce costs, increase productivity, and ultimately boost profitability. The company uses rapid and non-lethal blood analysis for fish health monitoring.

Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring the global voice of patients regarding launched medicines. The company offers Medsmart, an application that collects comprehensive data about medication adherence, including how, why, and what patients are taking. Its services include PatientMetRx®, a social intelligence platform that employs artificial intelligence and natural language processing to transform unstructured feedback from patients into actionable insights for pharmaceutical companies. This platform allows clients to utilize large language models to access curated patient and healthcare professional experiences, thereby enabling data-driven decision-making. Talking Medicines also provides a real-world persona data service with monthly updates, digital focus groups for surveys and questionnaires, and custom solutions tailored to specific pharmaceutical needs. Established in 2013 and rebranded in December 2015, the company serves the pharmaceutical and healthcare sectors, aiming to enhance marketing effectiveness and improve patient health outcomes through advanced patient insights.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative solutions for extracorporeal treatments. The company's flagship product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures such as dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes in long-term dialysis treatments.

PneumoWave is a company focused on developing advanced real-time monitoring solutions for patients with respiratory conditions. Utilizing proprietary sensor technology and an AI-driven digital therapeutic software platform, PneumoWave enables patients and healthcare providers to track respiratory rates and performance outside of clinical settings, such as at home or work. The company's innovative biosensors continuously capture and wirelessly transmit data for analysis, allowing for the accurate detection of various respiratory adverse events. This system includes an alert mechanism that promptly notifies healthcare professionals, facilitating timely interventions and improving patient outcomes. By enabling doctors to better manage medication use, identify early signs of deterioration, and reduce hospital admissions and in-person appointments, PneumoWave aims to transform respiratory care through proactive monitoring and intervention.

BioCaptiva is a company focused on advancing liquid biopsy technology for the early diagnosis and monitoring of challenging-to-detect cancers. The company's innovative platform captures circulating free DNA from patients' blood in greater quantities than existing methods, addressing the limitations of current liquid biopsy tests. By enhancing the ability to detect and monitor cancer, BioCaptiva aims to provide healthcare professionals with improved tools for disease management, ultimately transforming the landscape of cancer diagnostics.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Asklepios BioPharmaceutical is a biotechnology company focused on developing adeno-associated virus (AAV) gene therapies aimed at treating genetic disorders and rare diseases. Established in 2001 and headquartered in Research Triangle Park, North Carolina, the company possesses proprietary AAV technology and manufacturing capabilities, as well as a robust pipeline of clinical programs. Its pipeline includes clinical-stage therapies for Pompe disease and congestive heart failure, alongside a diverse array of preclinical candidates targeting neuromuscular and central nervous system diseases. Additionally, Asklepios has out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform features Pro10, a proprietary cell line manufacturing process, complemented by an extensive library of AAV capsids and promoters, supporting advancements in genetic medicine through global research collaborations and innovative delivery methods.

Manus Neurodynamica Ltd is a company based in North Shields, United Kingdom, established in 2008. It specializes in the development of medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson’s disease. The company’s innovative device serves as a triage tool that facilitates early diagnosis by analyzing minute limb and hand movements to quantify fine motor skills. This technology, coupled with advanced analytical software, enables clinicians to effectively assess patient movement parameters, thereby enhancing the accuracy of diagnoses and improving the efficiency of neuromotor services. Manus Neurodynamica's solutions are utilized in various settings, including academic research and pharmaceutical studies, as well as in non-medical applications.

SHE Software Ltd. is a provider of health and safety software solutions aimed at minimizing workplace risks. Founded in 1993 and based in East Kilbride, United Kingdom, the company specializes in its flagship product, Assure, which facilitates comprehensive health and safety management through features such as incident reporting, risk assessments, training record management, and contractor regulation. SHE Software also offers various modules that cover risk assessment, incident management, asset management, behavioral management, and environmental assessments, making it applicable across multiple sectors, including healthcare, construction, manufacturing, and education. The company delivers its software via desktop, web, cloud, and mobile platforms, ensuring broad accessibility and engagement. With a focus on innovation, SHE Software is positioned at the forefront of the evolving health and safety landscape, leveraging advancements in cloud computing and predictive analytics to enhance productivity and safety assurance for its clients.

Current Health Limited is a healthcare technology company based in Edinburgh, United Kingdom, that specializes in wearable devices for monitoring patient vitals. Founded in 2014 and originally known as Snap40 Limited, the company rebranded in December 2018. Current Health's devices are designed to measure critical health indicators such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, enabling early identification of potential health issues. Their patient monitoring platform facilitates the management of patients at home by collecting and analyzing data to detect and predict health deterioration. This allows patients to share daily activities, report symptoms, and complete structured questionnaires, ultimately helping healthcare providers reduce risks and costs associated with patient care.

Current Health Limited is a healthcare technology company based in Edinburgh, United Kingdom, that specializes in wearable devices for monitoring patient vitals. Founded in 2014 and originally known as Snap40 Limited, the company rebranded in December 2018. Current Health's devices are designed to measure critical health indicators such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, enabling early identification of potential health issues. Their patient monitoring platform facilitates the management of patients at home by collecting and analyzing data to detect and predict health deterioration. This allows patients to share daily activities, report symptoms, and complete structured questionnaires, ultimately helping healthcare providers reduce risks and costs associated with patient care.

Adaptix Limited, established in 2009 and headquartered in Oxford, UK, specializes in designing and manufacturing innovative 3D radiology imaging equipment for X-ray applications. The company's core product is a miniaturized, flat panel X-ray source that can be integrated into existing product lines, enabling manufacturers to offer low-dose 3D imaging capabilities at a more affordable price point and with enhanced portability. Adaptix's solutions are used in various medical fields, including bedside chest imaging, extremity imaging, dental imaging, and breast imaging, with the potential to improve diagnostic accuracy for conditions like cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. The company's technology, based on a pixelated array made in a semiconductor foundry, is protected by patents and leverages existing technologies from various industries. Adaptix's products are components intended for integration by X-ray systems manufacturers, who are responsible for product qualification, validation, and regulatory compliance.

Aiber is a company that develops innovative software and medical support systems aimed at enhancing emergency care in international first response scenarios. By utilizing Bluetooth sensors, Aiber's solutions enable wireless monitoring of vital signs, facilitating the detection of patient deterioration or improvement. Their medical-grade sensors empower crews to effectively manage medical emergencies in various environments, including air and sea travel. This technology allows for the seamless sharing of vital sign data with ground-based medical providers, ensuring consistent and informed care for passengers during flights. Overall, Aiber is dedicated to improving medical response capabilities and supporting remote healthcare initiatives.

Aiber is a company that develops innovative software and medical support systems aimed at enhancing emergency care in international first response scenarios. By utilizing Bluetooth sensors, Aiber's solutions enable wireless monitoring of vital signs, facilitating the detection of patient deterioration or improvement. Their medical-grade sensors empower crews to effectively manage medical emergencies in various environments, including air and sea travel. This technology allows for the seamless sharing of vital sign data with ground-based medical providers, ensuring consistent and informed care for passengers during flights. Overall, Aiber is dedicated to improving medical response capabilities and supporting remote healthcare initiatives.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative solutions for extracorporeal treatments. The company's flagship product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures such as dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes in long-term dialysis treatments.

Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring the global voice of patients regarding launched medicines. The company offers Medsmart, an application that collects comprehensive data about medication adherence, including how, why, and what patients are taking. Its services include PatientMetRx®, a social intelligence platform that employs artificial intelligence and natural language processing to transform unstructured feedback from patients into actionable insights for pharmaceutical companies. This platform allows clients to utilize large language models to access curated patient and healthcare professional experiences, thereby enabling data-driven decision-making. Talking Medicines also provides a real-world persona data service with monthly updates, digital focus groups for surveys and questionnaires, and custom solutions tailored to specific pharmaceutical needs. Established in 2013 and rebranded in December 2015, the company serves the pharmaceutical and healthcare sectors, aiming to enhance marketing effectiveness and improve patient health outcomes through advanced patient insights.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Adaptix Limited, established in 2009 and headquartered in Oxford, UK, specializes in designing and manufacturing innovative 3D radiology imaging equipment for X-ray applications. The company's core product is a miniaturized, flat panel X-ray source that can be integrated into existing product lines, enabling manufacturers to offer low-dose 3D imaging capabilities at a more affordable price point and with enhanced portability. Adaptix's solutions are used in various medical fields, including bedside chest imaging, extremity imaging, dental imaging, and breast imaging, with the potential to improve diagnostic accuracy for conditions like cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. The company's technology, based on a pixelated array made in a semiconductor foundry, is protected by patents and leverages existing technologies from various industries. Adaptix's products are components intended for integration by X-ray systems manufacturers, who are responsible for product qualification, validation, and regulatory compliance.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative solutions for extracorporeal treatments. The company's flagship product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures such as dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes in long-term dialysis treatments.

Adaptix Limited, established in 2009 and headquartered in Oxford, UK, specializes in designing and manufacturing innovative 3D radiology imaging equipment for X-ray applications. The company's core product is a miniaturized, flat panel X-ray source that can be integrated into existing product lines, enabling manufacturers to offer low-dose 3D imaging capabilities at a more affordable price point and with enhanced portability. Adaptix's solutions are used in various medical fields, including bedside chest imaging, extremity imaging, dental imaging, and breast imaging, with the potential to improve diagnostic accuracy for conditions like cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. The company's technology, based on a pixelated array made in a semiconductor foundry, is protected by patents and leverages existing technologies from various industries. Adaptix's products are components intended for integration by X-ray systems manufacturers, who are responsible for product qualification, validation, and regulatory compliance.

Reactec Ltd., established in 2001 and headquartered in Edinburgh, UK, specializes in vibration engineering consultancy. The company focuses on mitigating hand-arm vibration (HAV) risks through innovative solutions. Reactec's core product, the Reactec Analytics Platform, integrates wearable technology and online systems to automate HAV risk monitoring and reporting, enabling employers to comply with EU regulations and protect workers from HAVS. The platform offers real-time exposure tracking, identifies risk trends, and provides insights into tool performance and utilization, helping employers manage worker efficiency and welfare. Additionally, Reactec offers HAVWEAR monitors, HAVMETER for risk assessment, and tool vibration testing solutions.

Citruslabs specializes in streamlining clinical trials, supporting research organizations of all sizes. Its platform facilitates patient recruitment and retention by offering a network of health applications that engage users with educational content on physical exercises, nutrition, games, and clinical trial information. This data is then shared with healthcare clients, helping them identify and connect with suitable trial candidates.

Caldan Therapeutics Ltd is a biotechnology company formed as a spinout from the University of Glasgow and the University of Southern Denmark. The company is focused on developing innovative therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases such as Type 2 Diabetes (T2D). The collaboration between Professors Graeme Milligan and Trond Ulven has led to the identification of these receptors as promising targets for addressing various aspects of T2D, including insulin secretion, sensitivity, and cellular protection. In addition to T2D, Caldan Therapeutics is exploring the potential of its technology to treat other conditions, including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Relitect Limited is a technology company based in Motherwell, United Kingdom, focused on developing innovative diagnostic solutions for the life sciences industry. Founded in 2014, Relitect specializes in a novel assay platform that enables label-free electrochemical detection of binding events. This proprietary technology allows for the highly sensitive analysis of proteins, small molecules, and nucleic acids, making it suitable for clinical diagnostics and research applications. By utilizing small sample volumes and a multiplexed format, Relitect's technology minimizes sample interference and eliminates the potential for cross-talk between labeled reagents, enhancing the accuracy of biomarker detection.

DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, and was incorporated in 2010 as a spin-out from the University of Edinburgh. The company specializes in a novel chemical-based system for the detection of nucleic acids and single nucleotide polymorphisms, distinguishing itself from existing enzymatic methods. DestiNA Genomics offers a range of reagents and probes for detecting nucleic acids and mutations, as well as probe sets and assays aimed at drug development and profiling. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. Additionally, DestiNA has established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technology in collaboration with local partners. The company is committed to advancing diagnostic capabilities in areas such as cancer biomarkers, inherited diseases, and infectious diseases.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

DYSIS Medical Ltd., established in 2002 and headquartered in Edinburgh, UK, specializes in designing, developing, manufacturing, and marketing non-invasive imaging systems for detecting cancerous and pre-cancerous lesions. Its flagship product is the DYSIS Colposcope, a digital colposcope that measures aceto-whitening reaction and generates an intuitive map for easier diagnosis. The company also offers accessories like disposable/reusable specula, diathermy loops, coagulation balls, and software for data management and DYSISmap development. With sales offices in Tampa (USA), Edinburgh (UK), and Athens (Greece), DYSIS Medical aims to improve healthcare outcomes globally.

Viopti was established in May 2009 to bring to market a range of innovative premium branded products for the contact lens user. The companies lead product is the contactspod, a unique disposable contact lens case that is pre filled with solution and provides the end user with a hygienic option for storing their contact lenses. The company has licensed the right to use the Polaroid brand across a range of products including eye drops and solutions. Polaroid is an iconic brand recognised and trusted globally. Viopti has been supported technically by IT partners Ote for solutions and regularity control and Wideblue for product development. Contactspod is the world's first, pre-filled, single use contact lens case. Hermetically sealed containing sterile multi-purpose solution, it is perfect when travelling and is ideal for spa's, beauty treatments & active sports. Contactspod is small, compact, convenient to carry around and easy to use. These are significant benefits for the traveller especially when flying, given today's baggage weight restrictions.

Blackford Analysis Ltd. is a software company based in Edinburgh, United Kingdom, that specializes in enhancing the comparison of medical images to improve productivity in healthcare settings. Founded in 2010 as a spin-out from the University of Edinburgh, the company develops a range of tools designed for seamless integration into existing imaging systems. Key products include the Blackford Workflow Server, which facilitates the deployment of pre-processing capabilities within hospital IT frameworks, and the Blackford Smart Localizer, which allows for quick comparisons of multiple imaging studies with a single click. Blackford's software leverages advanced algorithms and multi-core processing technologies to deliver significant time savings—typically between 10% and 20%—for clinicians. The company collaborates with various imaging system providers, such as Philips and Intelerad Medical Systems, as well as industries beyond diagnostic imaging, to enhance diagnostic confidence and patient outcomes. Blackford Analysis continues to expand its presence, with sales offices in the United States and the United Kingdom.

Viopti was established in May 2009 to bring to market a range of innovative premium branded products for the contact lens user. The companies lead product is the contactspod, a unique disposable contact lens case that is pre filled with solution and provides the end user with a hygienic option for storing their contact lenses. The company has licensed the right to use the Polaroid brand across a range of products including eye drops and solutions. Polaroid is an iconic brand recognised and trusted globally. Viopti has been supported technically by IT partners Ote for solutions and regularity control and Wideblue for product development. Contactspod is the world's first, pre-filled, single use contact lens case. Hermetically sealed containing sterile multi-purpose solution, it is perfect when travelling and is ideal for spa's, beauty treatments & active sports. Contactspod is small, compact, convenient to carry around and easy to use. These are significant benefits for the traveller especially when flying, given today's baggage weight restrictions.

Blackford Analysis Ltd. is a software company based in Edinburgh, United Kingdom, that specializes in enhancing the comparison of medical images to improve productivity in healthcare settings. Founded in 2010 as a spin-out from the University of Edinburgh, the company develops a range of tools designed for seamless integration into existing imaging systems. Key products include the Blackford Workflow Server, which facilitates the deployment of pre-processing capabilities within hospital IT frameworks, and the Blackford Smart Localizer, which allows for quick comparisons of multiple imaging studies with a single click. Blackford's software leverages advanced algorithms and multi-core processing technologies to deliver significant time savings—typically between 10% and 20%—for clinicians. The company collaborates with various imaging system providers, such as Philips and Intelerad Medical Systems, as well as industries beyond diagnostic imaging, to enhance diagnostic confidence and patient outcomes. Blackford Analysis continues to expand its presence, with sales offices in the United States and the United Kingdom.

Actual Analytics Limited specializes in behavior analysis solutions for scientific research, leveraging advanced video analysis technology to monitor animal behavior automatically. The company’s flagship products include ActualTrack, which tracks the movements of lab animals such as rodents, drosophila, and zebrafish, and Actual Home Cage Analysis (ActualHCA), which facilitates non-invasive data collection and automated analysis of behaviors in group-housed rodents. This technology is particularly valuable in drug development for diseases affecting the Central Nervous System, allowing researchers to streamline the monitoring process, reduce errors, and cut costs associated with manual observation. Established in 2009 and headquartered in Edinburgh, United Kingdom, Actual Analytics distributes its products in various markets, including the United States, Spain, Taiwan, China, and Germany.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.

DC Biosciences Ltd is a biotechnology company based in Dundee, United Kingdom, focused on providing innovative proteomics services and molecular biology solutions to pharmaceutical and biotech firms. Established in 2006 and rebranded from Dundee Cell Products Ltd in 2016, the company specializes in quantitative proteomics technologies that facilitate various preclinical activities in drug discovery. Its offerings include stable isotope labeling with amino acids in cell culture reagents, such as SILAC cell culture media and dialyzed sera, alongside click chemistry reagents. These products support crucial processes such as biomarker discovery and validation, as well as drug re-profiling and repositioning, enabling faster and safer drug development.

Syntropharma Limited is an emerging pharmaceutical company based in Melrose, United Kingdom, founded in 2005. The company specializes in the development and distribution of pharmaceutical products, particularly focusing on skin patches that deliver proven medicines for various diseases, including neurological disorders such as Alzheimer's disease and depression. By reformulating commercially successful generic compounds into transdermal applications, Syntropharma aims to enhance their clinical profiles. The company is committed to creating a pipeline of innovative transdermal products protected by strong intellectual property, which it plans to out-license to pharmaceutical partners for broader market reach.